Status:
TERMINATED
A Study Of PF-06263507 In Patients With Advanced Solid Tumors
Lead Sponsor:
Pfizer
Conditions:
Neoplasms
Carcinoma, Non Small Cell Lung
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
To assess the safety and tolerability at increasing dose levels of PF-06263507 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase ...
Eligibility Criteria
Inclusion
- Diagnosis of solid tumor that is advanced/metastatic and resistant to standard therapy or for which no standard therapy is available.
- Performance Status of 0 or 1.
- Adequate bone marrow, kidney, liver, and heart function.
Exclusion
- Brain metastases requiring steroids.
- Major surgery or anti-cancer therapy within 4 weeks of study treatment start.
- Active bacterial, fungal or viral infection.
Key Trial Info
Start Date :
August 8 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 29 2015
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT01891669
Start Date
August 8 2013
End Date
June 29 2015
Last Update
January 9 2019
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
2
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02215
3
Karmanos Cancer Institute
Detroit, Michigan, United States, 48201
4
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States, 19111